ArticleBlood cancer journal2018

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.

Oliver Ottmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.